128 related articles for article (PubMed ID: 2338290)
41. A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia.
Rossini F; Terruzzi E; Verga L; Larocca A; Marinoni S; Miccolis I; Giltri G; Isella M; Parma M; Pogliani EM
Support Care Cancer; 2005 Jun; 13(6):387-92. PubMed ID: 15599778
[TBL] [Abstract][Full Text] [Related]
42. Randomized comparison of ceftriaxone versus ceftriaxone plus amikacin for the empirical treatment of infections in patients with altered host defense: microbiological and clinical evaluation.
D'Antonio D; Fioritoni G; Iacone A; Dell'Isola M; Natale D; D'Arcangelo L; Betti S; Spadano A; Recchia A; Mastrangelo C
Chemotherapy; 1992; 38(6):420-7. PubMed ID: 1288967
[TBL] [Abstract][Full Text] [Related]
43. Piperacillin plus amikacin vs. piperacillin plus amikacin plus teicoplanin for empirical treatment of febrile episodes in neutropenic patients receiving quinolone prophylaxis.
Martino P; Micozzi A; Gentile G; Raccah R; Girmenia C; Mandelli F
Clin Infect Dis; 1992 Aug; 15(2):290-4. PubMed ID: 1387806
[TBL] [Abstract][Full Text] [Related]
44. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
45. Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients.
Verhagen CS; de Pauw B; de Witte T; Janssen J; Williams K; de Mulder P; Bothof T
Antimicrob Agents Chemother; 1987 Feb; 31(2):191-6. PubMed ID: 3551829
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of infectious outbreaks in neutropenic patients with a piperacillin and amikacin combination].
Calvo F; de Castro H; Brice P
Presse Med; 1986 Dec; 15(46):2353-7. PubMed ID: 2949286
[TBL] [Abstract][Full Text] [Related]
47. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
Ann Hematol; 1998 Feb; 76(2):73-80. PubMed ID: 9540761
[TBL] [Abstract][Full Text] [Related]
48. [Cefepime-amikacin combination in febrile neutropenic children with malignant hemopathy or tumor].
Marie-Cardine A; Schneider P; Blot N; Tron P; Vannier JP
Arch Pediatr; 2003 Apr; 10(4):307-12. PubMed ID: 12818750
[TBL] [Abstract][Full Text] [Related]
49. Aztreonam therapy in neutropenic patients with cancer.
Jones PG; Rolston KV; Fainstein V; Elting L; Walters RS; Bodey GP
Am J Med; 1986 Aug; 81(2):243-8. PubMed ID: 3526885
[TBL] [Abstract][Full Text] [Related]
50. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
[TBL] [Abstract][Full Text] [Related]
51. Management of fever in neutropenic patients with acute leukemia: current role of ceftazidime plus amikacin as empiric therapy.
Fanci R; Paci C; Martinez RL; Fabbri A; Pecile P; Leoni F; Longo G
J Chemother; 2000 Jun; 12(3):232-9. PubMed ID: 10877519
[TBL] [Abstract][Full Text] [Related]
52. Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients.
Anaissie EJ; Fainstein V; Bodey GP; Rolston K; Elting L; Kantarjian H; Cabanillas F; McCredie KB
Am J Med; 1988 Mar; 84(3 Pt 2):581-9. PubMed ID: 3279774
[TBL] [Abstract][Full Text] [Related]
53. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer.
Pession A; Prete A; Paolucci G
Chemotherapy; 1997; 43(5):358-66. PubMed ID: 9309370
[TBL] [Abstract][Full Text] [Related]
54. Review of amikacin usage in the EORTC trials.
Zinner SH
Am J Med; 1985 Jul; 79(1A):17-20. PubMed ID: 3895903
[TBL] [Abstract][Full Text] [Related]
55. Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients.
Rotstein C; Cimino M; Winkey K; Cesari C; Fenner J
Am J Med; 1988 Jul; 85(1A):36-43. PubMed ID: 3041817
[TBL] [Abstract][Full Text] [Related]
56. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
57. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia.
Rubin M; Hathorn JW; Marshall D; Gress J; Steinberg SM; Pizzo PA
Ann Intern Med; 1988 Jan; 108(1):30-5. PubMed ID: 3337513
[TBL] [Abstract][Full Text] [Related]
58. Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients.
Borbolla JR; López-Hernández MA; González-Avante M; DeDiego J; Trueba E; Alvarado ML; Jiménez RM
Chemotherapy; 2001; 47(5):381-4. PubMed ID: 11561142
[TBL] [Abstract][Full Text] [Related]
59. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients.
Liu CY; Wang FD
Chemotherapy; 1989; 35 Suppl 2():16-22. PubMed ID: 2692982
[TBL] [Abstract][Full Text] [Related]
60. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Marie JP; Vekhoff A; Pico JL; Guy H; Andremont A; Richet H
J Antimicrob Chemother; 1998 Jun; 41 Suppl D():57-64. PubMed ID: 9688452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
